Is Jardiance (empagliflozin) safe for administration via a feeding tube?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Jardiance Administration via Feeding Tube

Jardiance (empagliflozin) tablets should NOT be routinely administered via feeding tube as this is an off-label use not supported by the FDA drug label, and crushing tablets carries risks of dosing inaccuracy, tube occlusion, and uncertain drug bioavailability.

Key Considerations

FDA Label Guidance

The Jardiance prescribing information 1 describes empagliflozin as "tablets for oral use" without any specific instructions or approval for administration via enteral feeding tubes. The label does not address crushing, dissolving, or alternative administration methods, which means feeding tube administration falls outside the approved Summary of Product Characteristics 2.

Critical Safety Concerns

Formulation Issues:

  • Jardiance tablets contain a film coating with specific inactive ingredients (hypromellose, polyethylene glycol, talc, titanium dioxide, yellow ferric oxide) 1
  • Crushing destroys the tablet integrity and may affect drug stability and absorption
  • The drug's pharmacokinetic profile was established with intact tablets, not crushed formulations 1

Tube-Related Risks:

  • Solid dosage forms have higher incidence of tube occlusions, particularly with nasogastric and silicone PEG tubes 2
  • Drug-tube interactions can occur depending on tube material (polyurethane vs. silicone) 2
  • Site of delivery matters—gastric vs. jejunal placement can significantly alter drug bioavailability 2

Clinical Decision Algorithm

If feeding tube administration is being considered:

  1. Consult a pharmacist immediately 2—this is a Grade GPP strong consensus recommendation for any medication administered via feeding tube

  2. Evaluate alternatives first:

    • Can the patient's diabetes be managed with DPP-4 inhibitors (which have been studied in tube-fed patients)?
    • Is insulin a safer option given the clinical uncertainty?
    • Can SGLT2 inhibitor therapy be temporarily held if the patient's cardiovascular/renal benefits are not immediately critical?
  3. If no alternative exists and tube administration is deemed necessary:

    • Use only gastric tubes (not jejunal)—SGLT2 inhibitors require gastric absorption
    • Crush tablet immediately before administration to minimize exposure 2
    • Flush tube with 30 mL water before administration 2
    • Administer crushed medication alone (never mix with other drugs) 2, 3
    • Flush tube with 30 mL water after administration 2
    • Stop enteral feeding 1 hour before and after to avoid potential drug-formula interactions 2
    • Monitor glucose control closely—expect potentially reduced efficacy
    • Document this as off-label use with informed consent

Important Caveats

Hypoglycemia Risk: The risk of hypoglycemia may be unpredictable when crushing Jardiance, especially in patients on concomitant insulin or sulfonylureas 4. The altered absorption profile could lead to either reduced efficacy or unexpected peaks in drug levels.

Renal Function Monitoring: Jardiance causes an initial eGFR decrease of ~5 mL/min within 1-2 weeks 5. This physiologic effect must be distinguished from tube-related malabsorption or drug accumulation. Check renal function 2 weeks after initiating crushed administration.

Volume Depletion: SGLT2 inhibitors increase urinary volume 1. In tube-fed patients who may already have altered fluid status, this risk is amplified. Ensure adequate fluid administration through the tube (beyond medication flushes) and monitor for orthostatic hypotension, particularly in elderly patients 1.

DKA Risk: Euglycemic DKA remains a concern 4, 6. Tube-fed patients often have reduced oral intake or are NPO for procedures—both are DKA risk factors. Discontinue Jardiance 3-4 days before any scheduled surgery 4, 7.

Practical Reality

The evidence gap is substantial: No published studies specifically evaluate empagliflozin stability or bioavailability when crushed and administered via feeding tube 8, 9. The 2026 landscape analysis found that only 18% of drug labels discuss pharmacokinetic effects of enteral tube administration 8.

Best practice in real-world medicine: If a patient absolutely requires both SGLT2 inhibitor therapy AND feeding tube nutrition, consider transitioning to insulin-based glucose management until oral intake resumes. The cardiovascular and renal benefits of empagliflozin 4, 7, 5 must be weighed against the risks of off-label crushing and uncertain bioavailability.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.